Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Income towards Parent Company of -$24.8 million for Q1 2026, down 27.72% year-over-year from -$34.2 million in Q1 2025, and down 487.22% quarter-over-quarter from $6.4 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Income towards Parent Company for 6 consecutive years, with -$24.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 27.72% year-over-year to -$24.8 million; the TTM figure through Mar 2026 stood at -$60.5 million (up 22.77% YoY), while the FY2025 annual figure was -$160.1 million, down 1.18% from the prior year.
- Income towards Parent Company fell to -$24.8 million in Q1 2026 per OBIO's latest filing, from $6.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $6.4 million in Q4 2025 and bottomed at -$25.2 million in Q2 2024.
- Historically, Income towards Parent Company has averaged -$14.8 million across 5 years, with a median of -$16.1 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 8300.5% — and 2025, when it soared 139.71%.
- Orchestra BioMed Holdings' Income towards Parent Company stood at -$10.1 million in 2022, then fell by 23.72% to -$12.5 million in 2023, then decreased by 28.98% to -$16.1 million in 2024, then surged by 139.71% to $6.4 million in 2025, then tumbled by 487.22% to -$24.8 million in 2026.
- Business Quant data shows OBIO's Income towards Parent Company at -$24.8 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.29 Mn |
| Mar 31, 2026 | -24.76 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | -20.54 Mn |
| Jun 30, 2025 | -21.57 Mn |
| Mar 31, 2025 | -19.38 Mn |
| Dec 31, 2024 | -16.10 Mn |
| Sep 30, 2024 | -17.62 Mn |
| Jun 30, 2024 | -25.19 Mn |
| Mar 31, 2024 | -15.80 Mn |
| Dec 31, 2023 | -12.48 Mn |
| Sep 30, 2023 | -22.02 Mn |
| Jun 30, 2023 | -16.96 Mn |
| Mar 31, 2023 | -11.90 Mn |
| Dec 31, 2022 | -10.09 Mn |
| Sep 30, 2022 | -10.45 Mn |
| Jun 30, 2022 | -7.89 Mn |
| Mar 31, 2022 | -5.36 Mn |
| Dec 31, 2021 | -122,045.00 |
| Sep 30, 2021 | -124,445.00 |